What are the Risks with the Proposed Second Round of Clinical Trials with RDN? - Ron Waksman, MD

↳ This is a section part of Moment: CRT 2015 Technology & Innovation - Future Clinical Trial Designs and Regulatory Requirements to Assess Efficacy of Devices for the Treatment of Renal Denervation

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$20.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

What are the Risks with the Proposed Second Round of Clinical Trials with RDN? presented by Ron Waksman, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$20.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows
Physicians

Session Name: Future Clinical Trial Designs and Regulatory Requirements to Assess Efficacy of Devices for the Treatment of Renal Denervation

Track: Technology & Innovation

Learning Objectives

Updates in Renal Denervation and Hypertension Therapies

Other Components in this Moment

Patient Characteristics and Impact of Background Clinical Characteristics and Drug Therapies - Raymond Townsend, MD

Proposed Phase 1 Renal Denervation Trial Design in Stage 2 Hypertension - William B. White, MD

How to Follow Patients with Hypertension: Office vs. Ambulatory - Felix Mahfoud, MD

What are the Risks with the Proposed Second Round of Clinical Trials with RDN? - Ron Waksman, MD

FDA Pathway to Approval: Clinical Requirements for Renal Denervation - K. J. Cavanaugh, PhD

What is the Evidence from Surgical Sympathectomies? - V. Papademetriou, MD, DSc

Academic Requirements for Approval of Renal Denervation: Endpoints for the Studies - John C. Somberg, MD

Clinical Pathways for Renal Denervation Research for the Treatment of Refractory and Moderate Hypertension - Laura Mauri, MD

Separation of Sham and Hawthorne Effects - Paul A. Sobotka, MD

Is Renal Denervation a Viable Therapy for Moderate Hypertension? - Raymond Townsend, MD

Loading Simple Education